Biotech Values

[DewDiligence]

New survey: FDA-Approval Dates for GILD & ABBV/ENTA HCV Regimens

The PDUFA date for GILD’s Sovaldi + Ledipasvir regimen is 10/10/14; the PDUFA date for ABBV/ENTA’s 3-DAA regimen is 12/21/14. (Please see #msg-96696670 for the phase-3 data supporting these NDAs.)


Q1: When will FDA approve GILD’s Sovaldi + Ledipasvir regimen?

a) October or later
b) September or earlier


Q2: When will FDA approve ABBV/ENTA’s 3-DAA regimen?

a) December or later
b) October-November
c) September or earlier


To vote, please go to
http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=1418
and select surveys #158.